Page 2 - Glenmark Pharmaceuticals

Glenmark, Alembic Pharma, Sun Pharma recall drugs in US, says USFDA

Drug makers Glenmark, Alembic Pharmaceuticals and Sun Pharma are recalling products in the US due to manufacturing issues, according to the US health regulator. Mumbai-based Glenmark is recalling two products in the market, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, is recalling Carvedilol tablets, used to treat heart failure, hypertension, and heart attack, in multiple strengths. The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated. The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added. Glenmark initiated the Class II recall in August this year. USFDA said the company is also recalling 2

Glenmark Pharma Q1 results: Profit falls 86% to ₹47 cr, revenue down 5%

Gelnmark's India revenue stood at ₹1,239.9 crore, up 3.7 per cent Y-o-Y from ₹1,196.2 crore, driven by growth in cardiac, respiratory, and dermatology segments despite weakness in diabetes portfolio

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Stocks to Watch today, July 14: VIP Industries, Adani Green, NCC, DMart

Stocks to Watch today, July 14, 2025: Glenmark Pharma, Avenue Supermarts, RVNL and NCC are some of the top stocks to watch today

Near-term upsides from deal with AbbVie may be priced in Glenmark's stock

Glenmark's $700 million deal with AbbVie for ISB-2001 could unlock significant upside, though analysts note the potential is already priced in, with stock surging post-announcement

Glenmark Pharma soars 10%, hits 52-week high on cancer drug licensing deal

At 09:30 AM, Glenmark Pharma shares were trading at ₹2,094.40, up by 10 per cent on the National Stock Exchange.

Stocks to Watch today, July 11: TCS, IREDA, ZEE, HUL, Tata Steel

Stocks to Watch today, July 11, 2025: TCS, IREDA, Glenmark Pharmaceuticals, HUL and Tata Steel are some of the top stocks to watch today

Glenmark arm inks $700 million licensing deal with US-based AbbVie

IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million

Glenmark Pharma's unit, Abbvie sign global licensing deal for cancer drug

Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China

Glenmark hits new high; zooms 37% in 2 months; what's driving pharma stock?

Since June 25, in 12 trading days, the stock has surged 12% after the company launched the lung cancer treatment drug Tevimbra in India, following the approval by the CDSCO.

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra

Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation.

Glenmark Pharma launches lung cancer treatment drug Tevimbra in India

Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-clas

Glenmark Pharma rises 2% as company to launch blood cancer treatment drug

Glenmark Pharma shares gained 2 per cent in trade as company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India

Glenmark set to launch blood cancer treatment drug Brukinsa in India

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five B-cell blood cancers with proven safety and efficacy

Stocks to buy today, June 5: Glenmark Pharma, M&M among analyst top picks

Stocks to buy today, June 5: Analyst at Religare Broking has recommended buying Glenmark Pharma, M&M and one more stock with upside potential

Glenmark's cancer drug shows strong results in early trial for Myeloma

In the dose-escalation stage of the trial, 35 patients were treated, most of whom had received a median of six prior therapies

Stock Market Close Highlights: Sensex jumps 455 points, Nifty at 25,001; all sectors settle in green

Sensex Today | Stock Market Close Highlights Monday, May 26, 2025: Among the Sensex constituents, 22 out of 30 stocks ended higher, with gains led by M&M, HCL Tech, Tata Motors, and Nestle India

Stocks to Watch, May 26: JSW Steel, NTPC, Glenmark Pharma, ONGC, Info Edge

Stocks to Watch on Monday: JSW Steel, NTPC, Glenmark Pharma, ONGC, Transrail Lighting, Info Edge and Lloyds Engineering Works are among the stocks to watch today, May 26, 2025

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America